|
 Novartis plans to manufacture the mRNA molecules that the two-shot
vaccine is based on as well as "bulk drug product" for up to 50
million doses by the end of 2021 and up to a further 200 million
doses in 2022, the two companies said in statements on Thursday.
Delivery from the manufacturing site in Kundl, Austria, is expected
to start in summer 2021, they added.
(Reporting by Ludwig Burger, editing by Thomas Escritt)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
